BetterLife Pharma Welcomes New Board Member
BetterLife Pharma Inc. is thrilled to announce the appointment of Dr. Steven Sangha to its Board of Directors. Dr. Sangha brings with him a wealth of experience, with over 25 years in business, particularly in investment banking and business development. This strategic addition comes at a critical time for the company as it continues its mission to develop innovative solutions for mental health disorders.
Dr. Sangha's Impressive Background
Dr. Sangha has had an illustrious career, marked by significant contributions to both public company governance and financial management. His extensive experience in overseeing compliance has been pivotal in his roles, leading him to establish a successful Private Fund Family Office. He holds a Doctorate of Dental Surgery from the University of Western Ontario and a Bachelor of Pharmaceutical Science from the University of British Columbia, enhancing his qualifications to guide BetterLife's initiatives.
Insights from Dr. Sangha
Expressing his enthusiasm about joining BetterLife, Dr. Sangha stated, "I am honored and excited to join BetterLife as a board member. I have been a long-time supporter and have now become the largest shareholder of BetterLife over the past few years. I believe BETR-001 is the best asset in its class and will be disruptive to help those suffering from depression, anxiety, PTSD, and addiction. I am looking forward to getting BETR-001 to the finish line so it can proceed with human clinical trials in the very near future." His commitment to BetterLife's vision underscores his belief in the potential impact of the company's products.
Expertise to Propel Biotech Development
Ahmad Doroudian, CEO of BetterLife, expressed his excitement over Dr. Sangha's appointment, remarking, "We are extremely pleased to welcome Dr. Sangha to our Board of Directors. He brings a wealth of experience in the biotech space, which will be very valuable as we execute our plans to develop non-hallucinogenic compounds to treat psychiatric and neurological disorders." His experience and network within the investment community are expected to greatly benefit the company's future endeavors.
About BetterLife Pharma
BetterLife Pharma Inc. is an emerging biotechnology company dedicated to developing and commercializing innovative compounds targeting neuro-psychiatric and neurological disorders. The company is notably focused on two promising compounds: BETR-001 and BETR-002.
Understanding BETR-001
BETR-001 is currently in preclinical and IND-enabling studies. This unique, non-hallucinogenic, and non-controlled LSD derivative stands out for its ability to be self-administered due to its unregulated status. With a synthesis patent that successfully minimizes regulatory hurdles, BetterLife aims to advance this compound for treating major depressive disorders, anxiety, and neuropathic pain, among other conditions.
Insights into BETR-002's Potential
Concurrently, BETR-002 is also undergoing preclinical and IND-enabling studies. This compound is derived from honokiol, the active ingredient found in magnolia bark that boasts anxiolytic properties. BetterLife is pursuing a patent for its formulations that address anxiety disorders, including those associated with benzodiazepine dependency.
Strategic Direction for Future Development
In addition to these promising candidates, BetterLife also possesses a drug candidate aimed at treating viral infections and is exploring strategic alternatives for its continued development. This holistic approach positions BetterLife favorably within the ever-evolving biotech landscape, as the company seeks to address significant unmet needs in the areas of mental health and beyond.
For further information about BetterLife Pharma and its developments, feel free to reach out to:
David Melles, Investor Relations Manager
Email: David.Melles@blifepharma.com
Phone: 1-778-887-1928
Frequently Asked Questions
What is BetterLife Pharma focused on?
BetterLife Pharma is focused on developing and commercializing therapies for neuro-psychiatric and neurological disorders.
Who is the newest member of BetterLife’s Board of Directors?
Dr. Steven Sangha has been appointed as the new member of the Board of Directors.
What compounds is BetterLife developing?
The company is developing BETR-001 and BETR-002 to address significant mental health challenges.
What is the unique feature of BETR-001?
BETR-001 is a non-hallucinogenic LSD derivative that can be self-administered due to its unregulated status.
How can I contact BetterLife’s Investor Relations?
You can contact David Melles, the Investor Relations Manager, via email or phone for inquiries.
